These guidelines are intended to provide guidance for the preparation for GCP inspections carried out by SFDA, which may take place before, during or after the conduction of clinical trials, as part of the verification of applications for drug registration, or as a follow-up to the granting of authorization.
Last Modified Date: 27/02/2022 - 8:28 AM Saudi Arabia Time
Please tell us why (select up to two options)